[1] Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer[J].Eur Respir Rev,2013,22(129):265-272.
[2] Tomassetti S,Gurioli C,Ryu JH,et al.The impact of lung cancer on survival of idiopathic pulmonary fibrosis[J].Chest,2015,147(1):157-164.
[3] Grimminger F,Schermuly RT,Ghofrani HA.Targeting non-malignant disorders with tyrosine kinase inhibitors[J].Nat Rev Drug Discov,2010,9(12):956-970.
[4] Beyer C,Distler JH.Tyrosine kinase signaling in fibrotic disorders:translation of basic research to human disease[J].Biochim Biophys Acta,2013,1832(7):897-904.
[5] Turner N,Grose R.Fibroblast growth factor signalling:from development to cancer[J].Nat Rev Cancer,2010,10(2):116-129.
[6] Wesche J,Haglund K,Haugsten EM.Fibroblast growth factors and their receptors in cancer[J].Biochem J,2011,437(2):199-213.
[7] Lieu C,Heymach J,Overman M,et al.Beyond VEGF:inhibition of the fibroblast growth factor pathway and antiangiogenesis[J].Clin Cancer Res,2011,17(19):6130-6139.
[8] Beenken A,Mohammadi M.The FGF family:biology,pathophysiology and therapy[J].Nat Rev Drug Discov,2009,8(3):235-253.
[9] Desai A,Adjei A.FGFR signaling as a target for lung cancer therapy[J].J Thorac Oncol,2016,11(1):9-20.
[10] Tiseo M,Gelsomino F,Alfieri R,et al.FGFR as potential target in the treatment of squamous non small cell lung cancer[J].Cancer Treat Rev,2015,41(6):527-539.
[11] Ahmad I,Iwata T,Leung HY.Mechanisms of FGFR-mediated carcinogenesis[J].Biochim Biophys Acta,2012,1823(4):850-860.
[12] Dutt A,Ramos AH,Hammerman PS,et al.Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer[J].PLoS One,2011,6(6):e20351.
[13] Wu YM,Su F,Kalyana-Sundaram S,et al.Identification of targetable FGFR gene fusions in diverse cancers[J].Cancer Discov,2013,3(6):636-647.
[14] Dienstmann R,Rodon J,Prat A,et al.Genomic aberrations in the FGFR pathway:opportunities for targeted therapies in solid tumors[J].Ann Oncol,2014,25(3):552-663.
[15] Marek L,Ware KE,Fritzsche A,et al.Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells[J].Mol Pharmacol,2009,75(1):196-207.
[16] Semrad TJ,Mack PC.Fibroblast growth factor signaling in non-small-cell lung cancer[J].Clin Lung Cancer,2012,13(2):90-95.
[17] Kim HR,Kim DJ,Kang DR,et al.Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer[J].J Clin Oncol,2013,31(6):731-737.
[18] Cihoric N,Savic S,Schneider S,et al.Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer[J].Br J Cancer,2014,110(12):2914-2922.
[19] Weiss J,Sos ML,Seidel D,et al.Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer[J].Sci Transl Med,2010,2(62):62ra93.
[20] Heist RS,Mino-Kenudson M,Sequist LV,et al.FGFR1 amplification in squamous cell carcinoma of the lung[J].J Thorac Oncol,2012,7(12):1775-1780.
[21] Craddock KJ,Ludkovski O,Sykes J,et al.Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma[J].J Thorac Oncol,2013,8(11):1371-1377.
[22] 蒲丹,侯梅.成纤维生长因子受体非小细胞肺癌中的研究进展[J].中国肺癌杂志,2013,16(11):609-614.
[23] Greenman C,Stephens P,Smith R,et al.Patterns of somatic mutation in human cancer genomes[J].Nature,2007,446(7132):153-158.
[24] Liao RG,Jung J,Tchaicha J,et al.Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma[J].Cancer Res,2013,73(16):5195-5205.
[25] Capelletti M,Dodge ME,Ercan D,et al.Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma[J].Clin Cancer Res,2014,20(24):6551-6558.
[26] Presta M,Dell'Era P,Mitola S,et al.Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis[J].Cytokine Growth Factor Rev,2005,16(2):159-178.
[27] Tchaicha JH,Akbay EA,Altabef A,et al.Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC[J].Cancer Res,2014,74(17):4676-4684.
[28] Hanumegowda C,Farkas L,Kolb M.Angiogenesis in pulmonary fibrosis:too much or not enough?[J].Chest,2012,142(1):200-207.
[29] Woodcock HV,Molyneaux PL,Maher TM.Reducing lung function decline in patients with idiopathic pulmonary fibrosis:potential of nintedanib[J].Drug Des Devel Ther,2013,7:503-510.
[30] MacKenzie B,Korfei M,Henneke I,et al.Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis[J].Respir Res,2015,16:83.
[31] Ramos C,Becerril C,Montano M,et al.FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway[J].Am J Physiol Lung Cell Mol Physiol,2010,299(2):L222-231.
[32] Gupte VV,Ramasamy SK,Reddy R,et al.Overexpression of fibroblast growth factor-10 during both inflammatory and fibrotic phases attenuates bleomycin-induced pulmonary fibrosis in mice[J].Am J Respir Crit Care Med,2009,180(5):424-436.
[33] Ju W,Zhihong Y,Zhiyou Z,et al.Inhibition of α-SMA by the ectodomain of FGFR2c attenuates lung fibrosis[J].Mol Med,2012,18:992-1002.
[34] Yu ZH,Wang DD,Zhou ZY.Mutant soluble ectodomain of fibroblast growth factor receptor-2Ⅲc attenuates bleomycin-induced pulmonary fibrosis in mice[J].Biol Pharm Bull,2012,35(5):731-736.
[35] Joannes A,Brayer S,Besnard V,et al.FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro[J].Am J Physiol Lung Cell Mol Physiol,2016,310(7):L615-629.
[36] Richeldi L,Costabel U,Selman M,et al.Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis[J].N Engl J Med,2011,365(12):1079-1087.
[37] Ledermann JA,Hackshaw A,Kaye S,et al.Randomized phase Ⅱ placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer[J].J Clin Oncol,2011,29(28):3798-3804.
[38] Reck M,Kaiser R,Mellemgaard A,et al.Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1):a phase 3,double-blind,randomised controlled trial[J].Lancet Oncol,2014,15(2):143-155.
[39] Spagnolo P,Maher TM,Richeldi L.Idiopathic pulmonary fibrosis:Recent advances onpharmacological therapy[J].Pharmarcol Ther,2015,152:18-27.
[40] Kutluk Cenik B,Ostapoff KT,Gerber DE,et al.BIBF 1120(Nintedanib),a triple angiokinase inhibitor,induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer[J].Mol Cancer Ther,2013,12(6):992-1001.
[41] Kim Y,Hammerman PS,Kim J,et al.Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients[J].J Clin Oncol,2014,32(2):121-128.
[42] Chen J,Chen G,Yan Z,et al.TGF-beta1 and FGF2 stimulate the epithelial-mesenchymal transition of HERS cells through a MEK-dependent mechanism[J].J Cell Physiol,2014,229(11):1647-1659.
[43] Trueb B,Amann R,Gerber SD.Role of FGFRL1 and other FGF signaling proteins in early kidney development[J].Cell Mol Life Sci,2013,70(14):2505-2518.
[44] Davies H,Hunter C,Smith R,et al.Somatic mutations of the protein kinase gene family in human lung cancer[J].Cancer Res,2005,65(17):7591-7595.
[45] Roth GJ,Binder R,Colbatzky F,et al.Nintedanib:from discovery to the clinic[J].J Med Chem,2015,58(3):1053-1063.
[46] Shou Y,Hirano T,Gong Y,et al.Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer[J].Br J Cancer,2001,85(11):1706-1712.
[47] Brattstrom D,Bergqvist M,Hesselius P,et al.Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients[J].Lung Cancer,2002,37(1):57-63.